Double Point Ventures completed the acquisition of Lumos Pharma for $38m.

Double Point Ventures, an investment firm specializing in healthcare, completed the acquisition of Lumos Pharma, a clinical-stage biopharmaceutical company developing therapeutics for rare diseases, for $38m. "We are pleased to have finalized the Phase 3 trial design and to sign the Merger Agreement with DPV. I wish to thank my Lumos colleagues, the endocrine community, and our investors for supporting our efforts to develop oral LUM-201 and improve the lives of children with growth hormone deficiency. I believe this transaction with DPV offers the best path forward for the further development of LUM-201," Rick Hawkins, Lumos Pharma Chairman and CEO.